Research programme: G protein-coupled receptor modulators - Pfizer/TaiGen Biotechnology
Alternative Names: GPCR modulators - Pfizer/TaiGenLatest Information Update: 16 Mar 2022
Price :
$50 *
At a glance
- Originator TaiGen Biotechnology
- Class Small molecules
- Mechanism of Action G protein-coupled receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Inflammation
Most Recent Events
- 11 Mar 2022 Arena Pharmaceuticals has been acquired and merged into Pfizer
- 18 May 2007 Discontinued - Preclinical for Cancer in Taiwan (unspecified route)
- 18 May 2007 Discontinued - Preclinical for Inflammation in Taiwan (unspecified route)